DBV Technologies to Present New Data at ACAAI 2023
November 02 2023 - 3:30PM
DBV Technologies to Present New Data at ACAAI 2023
Montrouge, France, November 2, 2023
DBV Technologies to Present New Data at
ACAAI 2023
- New data to include
late-breaking abstract detailing interim 12-month results from the
ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX)
of Viaskin™ Peanut in peanut-allergic toddlers.
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced that new data on the use
of Viaskin™ Peanut (DBV712) 250 μg in peanut-allergic toddlers will
be presented at the American College of Allergy, Asthma &
Immunology (ACAAI) Annual Scientific Meeting, which is being held
Thursday, November 9 – Monday, November 13, 2023, in Anaheim,
CA.
A late-breaking oral abstract has been accepted
by the ACAAI and will be presented on the interim 12-month results
from the ongoing Phase 3 open-label extension to the EPITOPE trial
(EPOPEX) trial of Viaskin™ Peanut in peanut-allergic toddlers. The
presentation will be available on DBV’s website,
www.dbv-technologies.com, following the conclusion of the meeting
for those who are unable to attend.
This year’s meeting will also feature a “Product
Theater” on Individualizing Peanut Allergy Management: A Case-based
Panel Discussion. Drs. Douglas Mack, David Stukus, and Julie Wang
will engage in a discussion around the factors influencing peanut
allergy management, such as use of food challenges and effects of
comorbidities, using various patient scenarios. The Product Theater
is scheduled for Saturday, November 11, from 11:35 a.m. to 1:00
p.m. PST.
DBV is sponsoring the 32nd Annual FIT Bowl, a
game show-type competition that tests allergy, asthma, and
immunology knowledge of participating teams from training programs
around the country. The competition is set to be held on Saturday,
November 11, from 5:45 p.m. to 7:45 p.m. PST. In addition, DBV is a
2023 ACAAI Benefactor Level Corporate Council Member. The Company
will also host a booth in the ACAAI Exhibit Hall from Saturday,
November 11 – Monday, November 13th.
“We are very pleased to have a significant
presence at ACAAI again this year and add to the growing body of
data on the potential of Viaskin Peanut as a new treatment option
for peanut-allergic toddlers,” said Dr. Pharis Mohideen,
Chief Medical Officer of DBV Technologies. “With no FDA
approved treatments, toddlers and their families must practice
avoidance, which can be stressful and can significantly impact
quality of life. Our goal is to complete the remaining regulatory
steps in support of a Biologics License Application (BLA) as
quickly and efficiently as possible to potentially bring this novel
treatment to these patients in need.”
DBV Abstracts:
Late Breaking Abstract
Presentation
“EPOPEX, Efficacy and Safety of
Epicutaneous Immunotherapy in Peanut-allergic Toddlers: 1-year
Open-Label Extension to EPITOPE” will be presented by
Matthew Greenhawt, M.D., M.Sc., MBA, FACAAI, Children’s Hospital
Colorado, Aurora, CO.
- Abstract ID: LB010
- Presentation Date: Saturday,
November 11
- Presentation Time: 9:40 a.m. – 9:50
a.m. PST
- Session/location: Late-breaking
Oral Abstracts - Session 1: Food Allergy; Exhibit Hall C – ePoster
Area – LIVE Presentation Stage
Viaskin Peanut is the Company’s lead product
candidate designed to reduce the risk of allergic reactions due to
accidental exposure to peanuts. An investigational, non-invasive,
once-daily epicutaneous patch, Viaskin Peanut seeks to deliver
microgram quantities of peanut antigen to re-educate the immune
system. The safety and efficacy of Viaskin Peanut have not yet been
established by the U.S. Food and Drug Administration or the
European Medicines Agency.
About DBV TechnologiesDBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, and is DBV Technologies’ method of delivering biologically
active compounds to the immune system through intact skin. With
this new class of non-invasive product candidates, the Company is
dedicated to safely transforming the care of food allergic
patients. DBV Technologies’ food allergies programs include ongoing
clinical trials of Viaskin Peanut. DBV Technologies has global
headquarters in Montrouge, France, and North American operations in
Basking Ridge, NJ. The Company’s ordinary shares are traded on
segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345)
and the Company’s ADSs (each representing one-half of one ordinary
share) are traded on the Nasdaq Global Select Market (Ticker:
DBVT).
Forward Looking StatementsThis
press release may contain forward-looking statements and estimates,
including, but not limited to, statements regarding the therapeutic
potential of Viaskin™ Peanut and EPIT™ and DBV’s planned regulatory
and clinical efforts including timing and results of communications
with regulatory agencies, and the ability of any of DBV’s product
candidates, if approved, to improve the lives of patients with food
allergies. These forward-looking statements and estimates are not
promises or guarantees and involve substantial risks and
uncertainties. At this stage, DBV’s product candidates have not
been authorized for sale in any country. Among the factors that
could cause actual results to differ materially from those
described or project herein include uncertainties associated
generally with research and development, clinical trials and
related regulatory reviews and approvals. A further list and
description of risks and uncertainties that could cause actual
results to differ materially from those set forth herein can be
found in DBV Technologies’ regulatory filings with the Autorité des
Marchés Financiers (“AMF”), DBV Technologies’ filings and reports
with the U.S. Securities and Exchange Commission (“SEC”), and
future filings and reports made with the AMF and SEC. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements and estimates, which speak only as
of the date hereof. Other than as required by applicable law, DBV
Technologies undertakes no obligation to update or revise the
information contained in this Press Release.
Investor Contact Katie
Matthews+ 1 (857) 529-2363katie.matthews@dbv-technologies.com
Media ContactAngela
Marcucci+1 646-842-2393angela.marcucci@dbv-technologies.com
Viaskin and EPIT are trademarks of DBV
Technologies.
DBV Technologies (TG:DBV)
Historical Stock Chart
From Dec 2024 to Jan 2025
DBV Technologies (TG:DBV)
Historical Stock Chart
From Jan 2024 to Jan 2025
